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Background/Aims
Antispasmodics such as octylonium are widely used to manage irritable bowel syndrome (IBS) symptoms. However, the efficacy 
and safety of another antispasmodic, tiropramide, remain uncertain. We aimed to evaluate the efficacy and safety of tir-
opramide compared with octylonium in patients with IBS.
Methods
In this multicenter, randomized, non-inferiority trial, 287 patients with IBS (143 receiving tiropramide and 144 octylonium) 
were randomly allocated to either tiropramide 100 mg or octylonium 20 mg t.i.d (means 3 times a day) for 4 weeks. Primary
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endpoint was the mean change of abdominal pain from baseline assessed by visual analogue scales (VAS) score after 4 weeks 
of treatment. Secondary endpoints were the changes in abdominal pain from baseline at week 2 and in abdominal discomfort 
at weeks 2 and 4, using VAS scores, patient-reported symptom improvement including stool frequency and consistency, using 
symptom diaries, IBS-quality of life (IBS-QoL), and depression and anxiety, at week 4. 
Results
The VAS scores of abdominal pain at week 4, were significantly decreased in both tiropramide and octylonium groups, but 
the change from baseline did not differ between the 2 groups (difference, -0.26 mm; 95% CI, -4.33-3.82; P = 0.901). 
Abdominal pain and discomfort assessed using VAS scores, diaries, and IBS-QoL were also improved by both treatments, and 
the changes from baseline did not differ. The incidence of adverse events was similar in the 2 groups, and no severe adverse 
events involving either drug were observed.
Conclusions
Tiropramide is as effective as octylonium in managing abdominal pain in IBS, with a similar safety profile.
(J Neurogastroenterol Motil 2014;20:113-121)
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Introduction
Irritable bowel syndrome (IBS) is a functional bowel dis-
order characterized by abdominal pain or discomfort relieved by 
defecation and accompanied by a change in bowel habit.1 
According to epidemiologic studies in Korea, the prevalence of 
IBS was reported to be 6.6% overall, 7.1% in men and 6.0% in 
women.2 Patients with IBS are reported to seek healthcare fre-
quently, have poor health-related quality of life (QoL) and be re-
sponsible for high societal costs.3-5 Like other functional gastro-
intestinal (GI) disorders, the development of IBS and its symp-
toms are associated with multifactorial pathophysiology.6 
Moreover, symptoms even in an individual patient with IBS may 
have a different pathophysiology depending on various factors 
such as diet or emotional status. Therefore, therapy targeting a 
specific pathophysiology in IBS has been difficult, and symptom 
treatment focusing on major complaints of IBS or drug combina-
tion covering multiple pathophysiology has usually been applied 
to the management of IBS. 
Of multifactorial pathophysiology in IBS, colonic smooth 
muscle spasm has long been postulated to be responsible for ab-
dominal pain in IBS from clinical observations as well as some ex-
perimental evidences.7 Therefore, pharmacologic agents directly 
acting on smooth muscle or on cholinergic receptors, called as an-
tispasmodics, have been developed and used to control abdominal 
pain and discomfort in IBS. They may be classified as smooth 
muscle relaxants or agents with anti-cholinergic or anti-muscar-
inic property. 
One of the antispasmodics, tiropramide, is a derivative of ty-
rosine, and exerts a spasmolytic effect on the intestine through re-
ducing Ca2+ release into intestinal smooth muscle, rather than 
acting on the enteric nervous system.8,9 In a double-blind, place-
bo-controlled, randomized trial, tiropamide led to symptom im-
provement in terms of total symptom scores for 4 weeks, com-
pared with 3 weeks in the placebo group; in addition, at week 4 
abdominal pain was only improved in the tiropramide group.10 
Also in a Korean study of similar design involving 63 patients 
with IBS, tiropramide improved overall symptom scores and de-
creased abdominal pain at weeks 2 and 4 (78.2% of the treatment 
group with tiropramide and 40.5% of placebo group).10
Another antispasmodic, octylonium, also modifies Ca2+ flux-
es in the intestinal smooth muscle, with direct myolytic properties 
similar to tiropramide.11,12 Previously, octylonium has already 
been proven to be more effective in reducing IBS symptoms than 
placebo.13-15 However, there have been few large-scale clinical tri-
als comparing tiropamide with antispasmodics of proven efficacy 
in IBS patients. Therefore, this study aimed at evaluating the effi-
cacy and safety profile of tiropamide in IBS patients compared 
with octylonium.
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Figure 1. The study design. VAS, 
visual analogue scale; IBS-QoL, irritable
bowel syndrome-quality of life; BDI, 
Beck depression inventory; BAI, Beck 
anxiety inventory.
Materials and Methods
Study Patients
Eligible patients were 20 to 75 years of age; had been diag-
nosed with IBS (as assessed according to the Rome III diagnostic 
criteria for IBS); complained of abdominal pain or discomfort at 
least 2 times per week for the 2-week run-in period; had visual 
analogue scale (VAS) scores over 30 mm for abdominal pain dur-
ing the randomization period. Patients who fit the study criteria 
had a run-in period of at least 2 weeks during which all IBS-re-
lated medications, and concomitant medications were stopped. 
Exclusion criteria included a history of inflammatory bowel 
disease, lactose intolerance, uncontrolled diabetes (haemoglobin 
A1C > 8%) or hypertension (systolic or diastolic blood pressure 
of ≥ 140/90 mmHg), psychiatric disorder requiring medication, 
malignancy of organs other than digestive (except for cases with 
no recurrence for over 5 years since treatment), laparoscopic or 
open abdominal surgery (except for appendectomy), renal or 
hepatic disease, glaucoma, and prostate hyperplasia. Those with a 
history of the following diseases within the previous 6 months 
were also excluded; peptic ulcer disease, GI bleeding, gastro-
esophageal reflux disease, intestinal stenosis or obstruction, in-
fectious diarrhea, and pancreatic insufficiency. Patients were ex-
cluded if they were intolerable of or sensitive to, study drug, had a 
history of alcohol or drug addiction, or were expected to take any 
contraindicated medication during the study period. Pregnant or 
lactating women and women of childbearing age not using con-
traception, were also excluded. 
Study Design 
This was a multicenter (20 centers), randomized, dou-
ble-blind, parallel-group, non-inferiority comparative study con-
ducted in South Korea from May 2012 to April 2013. The study 
protocol was approved by the Institutional Review Board of each 
study center and conducted in accordance with the ethical princi-
ples based on the Declaration of Helsinki and Good Clinical 
Practice guidelines. 
For a run-in period of about 2 weeks, eligible subjects for 
screening were instructed to stop IBS-related medications and 
prohibited from other drugs. Following the screening phase of 2 
to 4 weeks, eligible patients were randomly assigned to either tir-
opramide (Tiropa; Dae Woong Pharma Korea Inc., Seoul, South 
Korea) 100 mg or octylonium (Menoctyl; DONG HWA 
PHARM, Seoul, South Korea) 20 mg, taken 3 times daily before 
meals for 4 weeks. Treatment assignments were carried out by a 
computer-generated randomization schedule that was designed 
to allocate patients to the 2 treatment arms in a 1:1 ratio. The sub-
jects were assigned to sequential allocation numbers at each site, 
and the medications were presented as 2 identically-appearing 
tablets containing 1 active drug and 1 placebo of each com-
parative drug to maintain the double blind condition. Follow-up 
visits during the study period were scheduled at weeks 2 and 4 to 
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Figure 2. Enrollment, randomization and follow-up in the study.
assess abdominal pain/discomfort using VAS, IBS quality of life, 
IBS symptoms including bowel habits using diaries, the Beck de-
pression inventory (BDI) and the Beck anxiety inventory (BAI), 
drug compliance and adverse events (Fig. 1). Written, informed 
consent was obtained from all subjects before enrollment.
Study Assessments
Efficacy 
The primary endpoint was the change in abdominal pain 
from baseline assessed by VAS scores after 4 weeks of treatment. 
The secondary endpoints included the change in abdominal pain 
from baseline by VAS scores at week 2, the change in abdominal 
discomfort from baseline by VAS scores at weeks 2 and 4, im-
provement of patients’ overall assessment at weeks 2 and 4, the 
change in IBS QoL from baseline at 4 weeks, the change in 
symptom improvement in abdominal pain and discomfort from 
baseline using symptom diaries (severity of symptoms and days of 
no symptoms), and stool frequency and form assessed by Bristol 
stool form scale and according to IBS subtypes. Symptom im-
provement was defined as “completely improved,” “considerably 
improved” or “slightly improved.” Percentages of symptom im-
provement include “completely, considerably and slightly im-
proved.” Symptom diaries assessed daily symptoms of abdominal 
pain and discomfort using VAS of 0 to 100 with 100 representing 
extreme symptom. The number of defecation per day and the 
most common stool consistency during the day were recorded us-
ing the Bristol stool form scale. IBS-QoL was assessed by asking 
patients to answer each question using a 5-point Likert scale (0 = 
none, 1 = mild, 2 = moderate, 3 = severe, 4 = extremely se-
vere). Exploratory end points were the changes in BDI and BAI 
from baseline. Each BDI or BAI was composed of 21 questions 
and assessed as “0 = do not feel at all,” “1 = feel a bit,” “2 = feel 
significantly,” and “3 = feel badly.” Confounding factors were 
baseline factors of efficacy including BDI and BAI.
Safety
Safety assessments included adverse events, and abnormal-
ities in laboratory findings and vital signs. 
Statistical Methods
We estimated the required sample size for this study from the 
data of a previous study which found a change in VAS for ab-
dominal pain from baseline as 23.6 mm with standard deviation 
Non-inferiority of Tiropramide to Octylonium in Managing IBS
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Table 2. Changes in Visual Analogue Scale Scores for Abdominal Pain From Baseline at Week 4
VAS score (mm) Tiropramide Octylonium Difference (95% CI) P-value
PPS n = 117 n = 128
    Baseline 47.50 ± 14.35 48.24 ± 12.82 　
    At week 4 24.02 ± 14.99 25.11 ± 16.47 　
    Change -23.49 ± 17.51 -23.13 ± 17.61 -0.35 (-4.78, 4.07) 0.875a
    In-group P-value < 0.001b < 0.001b
FAS n = 143 n = 144
    Baseline 47.53 ± 13.88 48.00 ± 12.78 　
    At week 4 24.49 ± 15.20 25.22 ± 16.63 　
    Change -23.04 ± 17.97 -22.78 ± 17.09 -0.26 (-4.33,3.82) 0.901a
    In-group P-value < 0.001b < 0.001b 　
aTwo sample t test, bPaired t test.
VAS, visual analogue scale; PPS, per-protocol set; FAS, full-analysis set.
Change = week 4 - Baseline.
The upper limit of the 97.5% CI at one-sided was 3.82 mm, which is lower than the margin of non-inferiority of 11 mm, indicating the non-inferiority of tiropramide to 
octylonium.
Values are means ± SD.
Table 1. Demographic and Baseline Characteristics of the Full 
Analysis Set
Characteristics 
Tiropramide
(n = 143)
Octylonium
(n = 144)
P-value
Age (yr)  0.908a
    Mean ± SD 44.48 ± 14.34 44.76 ± 14.90
    Median
      (Min, Max)
43.00
(20.00, 72.00)
44.00
(20.00, 73.00)
Sex (n [%]) 0.595b
    Male 68 (47.55) 73 (50.69)
    Female 75 (52.45) 71 (49.31) 　
BMI (kg/m2) 0.669a
    Mean ± SD 22.89 ± 3.14 23.00 ± 3.01
    Median
      (Min, Max)
22.60
(16.77, 33.50)
22.70
(16.91, 30.86)
　
Examination 
  methods (n [%])
0.499c
    Colonoscopy 143 (100.00) 142 (98.61)
    Colon study 0 (0.00) 2 (1.39) 　
Duration of IBS
  symptoms (yr)
0.519a
    Mean ± SD 7.75 ± 8.44 8.11 ± 7.97
    Median
      (Min, Max)
5.04
(0.56, 49.62)
5.70
(0.53, 48.30)
　
IBS subtypes 
  (n [%])
0.913c
    IBS-C 3 (2.10) 4 (2.78)
    IBS-D 38 (26.57) 40 (27.78)
    IBS-M 102 (71.33) 100 (69.44)
aWilcoxon’s rank sum test, bPearson’s chi-square test, cFisher’s exact test.
BMI, body mass index; IBS, irritable bowel syndrome; IBS-C, constipa-
tion-predominant IBS; IBS-D, diarrhea-predominant IBS; IBS-M, mixed type IBS.
(SD) of 25.0 mm.14 The margin of non-inferiority was assumed 
to be 11 mm, approximately half of 22.7 mm, which was the dif-
ference of the changes observed between the octylonium and the 
placebo groups. Based on these assumptions, a sample of 129 pa-
tients was needed for each study arm in order to have a power of 
90%, and α of 0.025 (one-sided), while allowing for a 15% drop-
out rate. The analyses were performed using full analysis set 
(FAS) and per protocol set (PPS). 
All efficacy analyses were conducted in the FAS population, 
which consisted of all randomized patients satisfying the in-
clusion and exclusion criteria who received at least one dose of 
study medication and had at least one post-baseline efficacy 
measurement. The primary efficacy analysis was based on the 
PPS, which included all patients within the FAS population who 
took more than 80% of their assigned drugs and had no major 
protocol violations such as violations of scheduled visits or ad-
ministration of contraindicated medication. 
The change in VAS for abdominal pain from baseline was 
evaluated by 2 sample t test. Seconday outcomes were compared 
by 2 sample t test or Wilcoxon’s rank sum test. Rates of symptom 
improvement were described as frequencies and percentages, and 
compared between groups by Pearson’s chi-square test or 
Fisher’s exact test. For safety variables including treatment emr-
gent adverse event (TEAE), adverse drug reaction, and serious 
adverse event, Pearson’s chi-square test or Fisher’s exact test was 
used to evaluate differences in incidence between groups. 
Changes in continuous variables from baseline after treatment 
were analyzed by 2 sample t test or Wilcoxon’s rank sum test, 
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Table 3. The Change From Baseline in Secondary Endpoints 
Tiropramide Octylonium P-value
VAS score for abdominal pain n = 143 n = 144 0.752a
    Baseline 47.53 ± 13.88 48.00±12.78
    At week 2 33.03 ± 17.06 34.12±16.73
    In-group P-value < 0.001b < 0.001b
VAS score for abdominal discomfort n = 143 n = 144
    Baseline 52.57 ± 15.61 52.71 ± 15.55
    At week 2 38.68 ± 19.65 38.02 ± 17.25 0.729a
    At week 4 29.41 ± 19.40 29.30 ± 17.42 0.917a
    In-group P-value < 0.001b < 0.001b
Percentages of symptom improvement n = 143 n = 144
    At week 2 79.72%, 114/143 74.31%, 107/144 0.276c
    At week 4 86.33%, 120/139 84.40%, 119/141 0.648c
    In-group P-value < 0.001b < 0.001b
BDI n = 143 n = 144 0.080d
    Baseline 14.83 ± 9.27 15.93 ± 9.34
    At week 4 11.97 ± 9.12 (4) 11.47 ± 8.57 (3)
    In-group P-value < 0.001b < 0.001b
BAI n = 143 n = 144 0.878d
    Baseline 14.50 ± 10.64 13.37 ± 8.76
    At week 4 10.22 ± 9.53 (4) 8.20 ± 6.89 (3)
    In-group P-value < 0.001b < 0.001b
IBS-QoL (total) n = 143 n = 144 0.070d
    Baseline 77.66 ± 27.57 79.46 ± 26.41
    At week 4 61.96 ± 24.07 61.1 ± 20.941 (1)
    In-group P-value < 0.001b < 0.001b
Stool frequency n = 38 n = 40 0.333a
    IBS-D
Baseline 5.18 ± 0.91  5.14 ± 0.85
At week 4 4.41 ± 1.10 (2) 4.63 ± 0.97 (2)
    In-group P-value < 0.001b < 0.001b
Stool consistency n = 38 n = 40 0.120d
    IBS-D
Baseline 2.64 ± 1.37 2.27 ± 1.36
At week 4 2.01 ± 1.07 (2) 1.89 ± 1.06 (1)
    In-group P-value < 0.001b < 0.032b
aTwo sample t test, bPaired t test, cPearson’s chi-square test, dWilcoxon rank sum test.
VAS, visual analogue scale; BDI, Beck depression inventory BAI, Beck anxiety inventory IBS-QoL, irritable bowel syndrome-quality of life IBS-D, diarrhea 
predominant IBS. 
Values are means ± SD, ( ): number of dropout. Percentages of symptom improvement include “completely, considerably and slightly improved.”
while categorical variables, by Pearson’s chi-square test or 
Fisher’s exact test. Confounding factors such as BDI, BAI and 
baseline values of the efficacy variables were further analysed by 
ANCOVA or multiple logistic regression. A P-value of 0.05 was 
considered statistically significant. Statistical analyses were per-
formed using SAS (Enterprise Guide 4.3).
Results
Baseline Characteristics
Total of 356 patients were evaluated for study inclusion. 
After exclusion of 61 patients during the screening period, 295 
patients were randomized to either tiropramide or octylonium. 
Non-inferiority of Tiropramide to Octylonium in Managing IBS
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Table 4. Adverse Events During the Study
Event
Tiropramide
(n = 147) 
Octylonium
(n = 147)
Constipation 3 (2.04) 2 (1.36)
Dry mouth 2 (1.36) 1 (0.68)
Dyspepsia 2 (1.36) 2 (1.36)
Nausea 1 (0.68) 2 (1.36)
Headache 2 (1.36) 1 (0.68)
Chest pain 0 (0.00) 2 (1.36)
Nasopharyngitis 2 (1.36) 0 (0.00)
Myalgia 1 (0.68) 2 (1.36)
Serious adverse events
  Idiopathic thrombocytopenic
    purpura
1 (0.68) 0 (0.00)
  Intervertebral disc protrusion 0 (0.00) 1 (0.68)
The adverse events listed were reported by 2 or more patients in either treatment 
group and the serious adverse events listed were reported in 1 patient from each 
treatment group.
Values are presented as n (%).
Three percent of patients in the tiropramide group (4/143) and 
octylonium group (4/144) did not complete the study. Data on 
the remaining 287 patients were available for the FAS analysis: 
143 for tiropramide vs. 144 for octylonium. Data on 245 patients 
were available for the PPS analysis: 117 for tiropramide vs. 128 
for octylonium. A flowchart of patient progression through the 
study with reasons for premature discontinuation is presented in 
Fig. 2. Demographic and baseline characteristics of patients are 
presented in Table 1. Both treatment arms were well balanced for 
gender, age and severity of symptoms at baseline.
Efficacy
The PPS population comprised of 245 patients (117 in the 
test group and 128 in the control group). The mean changes of 
VAS scores for abdominal pain from baseline were -23.49 ± 
17.51 mm in the tiropramide group and -23.13 ± 17.61 in the 
octylonium group. The mean difference between the 2 groups 
was -0.26 mm in the FAS and -0.35 mm in the PPS, and the up-
per limit of the 97.5% CI at one-sided was 3.82 mm in the FAS 
and 4.07 mm in the PPS; these are below the margin of in-
feriority of 11 mm, indicating that tiropramide is not inferior to 
octylonium (Table 2). 
In secondary outcome analyses, VAS scores for abdominal 
pain at week 2 were significantly decreased in both groups (Table 
3). Significant improvement in abdominal pain and discomfort at 
weeks 2 and 4 using symptom diaries, and in IBS-QoL, BDI and 
BAI at week 4 were observed in both groups, however the differ-
ences between the groups were not significant. In the subgroup of 
IBS-D, stool frequency was decreased and stool consistency was 
improved by treatment. Furthermore, the degree of symptom re-
duction in abdominal pain using symptom diaries was higher in 
the tiropramide group than in the octylonium group from week 1 
(P = 0.033). 
After adjusting the baseline values of related factors, our 
analysis showed that all the factors based on symptom diaries, ex-
cept the change of IBS symptoms, did not differ in the 2 groups. 
IBS symptoms at week 4 using symptom diaries were reduced 
further compared to baseline in the tiropramide group than the 
octylonium group. 
Safety
Adverse events reported during the study are shown in Table 
4. TEAE was 10.88% (16/147) in the tiropramide group and 
12.24% (18/147) in the octylonium group, which included 28 
each. The safety profile of tiropramide was similar to that of 
octylonium. Adverse drug reactions were reported in 7 patients in 
the tiropramide group and 6 patients in the octylonium group, 
which included 17 and 9, respectively. Serious adverse events de-
veloped in one patient in each group, idiopathic thrombocyto-
penic purpura in the tiropramide group and intervertebral disc 
protrusion in the octilonium group, but were not related to the 
study drugs, and were improved without any sequelae. Laborato-
ry test results, when comparing those at screening period with 
those at last visit, showed no violation of safety regarding normal 
values, or the changes of direction and quantity. Vital signs did 
not change significantly from baseline in either group at weeks 2 
and 4. 
Discussion
The present study was designed to assess the non-inferiority 
of tiropramide compared to the proven antispasmodic, octylo-
nium, for managing IBS symptoms. This multicenter, random-
ized, double-blind, non-inferiority trial showed that 4-week treat-
ment with tiropramide improved abdominal pain and discomfort, 
patient-reported overall assessments of IBS symptoms, IBS-QoL, 
depression and anxiety, with no significant differences from octy-
lonium. These results demonstrate non-inferiority of tiropramide 
in efficacy and safety, compared with otiolonium. 
Tiropramide effectively and safely managed abdominal pain 
in the IBS patients. Our results showed that the change in VAS 
scores for abdominal pain from baseline was about 23.5 mm after 
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4-week treatment with tiropramide, similar to 23.6 mm observed 
after 4-week treatment with octylonium. The changes from base-
line between the 2 groups were not significantly different, and the 
upper limit of 95% CI was lower than the margin of inferiority in 
both the FAS and PPS populations, indicating non-inferiority of 
tiropramide compared to octylonium. In a previous study com-
paring tiroparmide with octylonium in IBS patients, the pro-
portion of patients whose abdominal pain was relieved by treat-
ment was higher in tiropramide group than in octylonium group 
at days 3 and 5 of medication, suggesting rapid drug action of 
tiropramide.16 Also, at the end of 30-day treatment, normal gut 
motility was restored in 88% of the tiropramide group compared 
with 47% of octylonium group.16  
The presumed mechanism of tiropramide in improving ab-
dominal pain is its antispasmodic effect on the intestine. In an an-
imal study using the isolated smooth muscle, tiropramide in-
hibited Ca2+ influx for the most part and, to a lesser extent, in-
creased the intracellular cyclic adenosine monophosphate (cAMP) 
levels.9 This study using rabbit also found that tiropamide in-
creased Ca2+ absorption into microvesicles and decreased the 
amount of Ca2+ released to stimulate the contraction of the 
smooth muscle by increasing cAMP; as a consequence the 
smooth muscle relaxed.9 In terms of the distribution of tir-
opramide, a study showed that the radioactivity of tiropramide 
lasted longer in the colon than in other organs after intravenous 
or oral administration,17 indicating relative colonic selectivity. 
Furthermore, the effect of tiropramide were more evident in the 
smooth muscle of the digestive, urinary and female genital tract 
than in those of the vessel, and in stimulated contractions rather 
than in spontaneous ones.17
In the present study, other advantages of tiropramide were 
observed compared with octylonium: tiropramide was effective 
earlier than octylonium; in the assessment using symptom diaries, 
the severity and degree of abdominal discomfort tended to be re-
duced further in the tiropramide group than in the octylonium 
group. Since this study was designed to evaluate the non-in-
feriority of tiropramide over octylonium, we could not conclude 
that tiropramide is more effective than octylonium, but we may at 
least speculate about this possibility, considering that assessment 
using symptom diaries is less biased than that using VAS, which 
is based on  patients’ rememberance of symptoms from the pre-
vious week. Taken together, there may be some advantage of tir-
oparmide over octylonium for managing IBS symptoms; this 
could be due to its colonic selectivity.
Regarding the safety of tiropramide, percentages of patients 
reporting adverse events were similar in both groups. Vital signs 
and labortory test results did not significantly change after a 
4-week treatment with either drug. It has been known that it does 
not affect neurotransmitters such as histamine, acetylcholine, and 
adrenaline, thus leading to a lower incidence of side effects than 
other antispasmodic agents. It was also found that tiropramide 
did not affect esophageal motility, including the pressure of the 
low esophageal sphincter, and the coordinated movements of the 
esophagus.18 Actually, both tiropramide and octylonium have 
been safely prescribed over the past ten years. Similarly, the pres-
ent study raised no safety concern.
In the subgroup of patients with diarrhea predominant IBS 
(IBS-D), tiropramide improved bowel habits. Its spasmolytic ef-
fect of the drug may be related to the improvement of bowel hab-
its in terms of stool frequency and consistency. These improve-
ments may also be explained by the fact that tiropramide can re-
store normal intestinal transit in patients with IBS-D having rap-
id intestinal transit, and are consistent with observations in a 
study on octylonium demonstrating improvements of bowel habit 
and abdominal pain and discomfort.14 Moreover, as previously 
mentioned, gut motility was normalized in 88% of the tir-
opramide group after 30-day treatment with tiropramide, against 
47% of the octylonium group.16 Considering the effect on bowel 
habit improvement in the subgroup of patients with IBS-D, there 
may be an additional benefit of tiropramide in patients with 
IBS-D, although the small number of patients with constipation 
predominant IBS (IBS-C) in our study might preclude us from 
concluding that the study drug is effective in patients with 
IBS-C. 
In this study, levels of depression and anxiety in the IBS pa-
tients were also improved by tiropramide. This may be in-
terpreted in terms of the brain-gut axis.19 Relief of abdominal 
pain may affect positively the emotional status of study patients. 
IBS-QoL was also improved. However, theses secondary out-
comes should be cautiously interpreted because there may be a 
variety of confounding factors. Placebo effects are known to be 
relatively high in IBS, ranging from 20% to 70%. This is believed 
to be partly due to a variety of physical and psychological factors 
affecting the brain-gut axis, which is thought to be involved in 
IBS pathophysiology. Therefore, studies of the treatment of IBS 
should be designed as randomized, double-blind, and place-
bo-controlled trials.20 The present study lacks a placebo control 
therefore could be limited in directly showing the superiority of 
tiropramide to placebo. However, this limitation in our study may 
be sufficiently compensated by previous evidence to demonstrate 
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the superiority of octylonium to placebo.13,14,21 Other limitations 
of our study include the relatively short period of treatment (only 
4 weeks) and the lower dose of octylonium than that used in the 
reference study (20 mg vs. 40 mg, t.i.d). However, the efficacy of 
both tiropramide and octylonium in improving symptoms of IBS 
was clearly demonstrated by our study results with statistical dif-
ferences between pre- and post-treatments.
In conclusion, our study demonstrates that treatment with 
tiropramide is effective and safe for managing IBS symptoms 
such as abdominal pain and discomfort, stool frequency and con-
sistency, IBS-QoL, depression and anxiety. Considering not 
enough data fully show the efficacy and safety of tiropramide in 
IBS patients, the present study should be a useful reference in 
IBS research and clinical practice for managing IBS patients. 
Further studies are required to elucidate the mechanism of action 
of tiropramide on intestine, particularly its pharmacodynamic and 
pharmacokinetic properties . 
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